Question 1

What is tesamorelin used for?

Accepted Answer

Tesamorelin (brand name Egrifta) is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Off-label, it is prescribed by anti-aging and functional medicine clinicians for visceral fat reduction, body composition optimization, and GH restoration in patients with age-related GH decline. Emerging research also shows promise for NAFLD/NASH and cognitive function.

Question 2

How much visceral fat can tesamorelin reduce?

Accepted Answer

In Phase III clinical trials, tesamorelin 2 mg daily reduced visceral adipose tissue (measured by CT scan) by approximately 15-18% from baseline after 26 weeks. This is a clinically meaningful reduction in the most metabolically dangerous fat compartment. However, visceral fat reaccumulates to near-baseline levels within 3-6 months of discontinuing treatment.

Question 3

Is tesamorelin better than sermorelin?

Accepted Answer

Tesamorelin has stronger clinical evidence, current FDA approval, enhanced stability, and more robust data for visceral fat reduction. Sermorelin is typically less expensive and has a long safety track record from its years as an approved drug. Both are GHRH analogs working through the same receptor. The choice often depends on whether clinical evidence or cost is the higher priority.

Question 4

Does tesamorelin cause insulin resistance?

Accepted Answer

Tesamorelin can modestly increase fasting glucose and HbA1c levels due to growth hormone's anti-insulin effects. In clinical trials, approximately 4% of tesamorelin-treated patients developed new-onset diabetes vs. about 2% on placebo. Monitoring of glucose metabolism is essential during treatment, especially in patients with pre-existing insulin resistance or pre-diabetes.

Question 5

How long does tesamorelin take to work?

Accepted Answer

IGF-1 levels increase within the first 2-4 weeks. Measurable visceral fat reduction typically becomes apparent on imaging at 12-16 weeks, with the Phase III trial primary endpoint measured at 26 weeks. Subjective improvements in sleep, energy, and recovery may be noticed earlier, within the first few weeks of treatment.

Question 6

Can I take tesamorelin without HIV?

Accepted Answer

Yes, tesamorelin can be prescribed off-label by physicians for non-HIV patients. The FDA approval is specifically for HIV lipodystrophy, but physicians have legal discretion to prescribe approved drugs for off-label uses. Many anti-aging and functional medicine clinics prescribe tesamorelin for visceral fat reduction and GH optimization in non-HIV patients.

Question 7

What happens when you stop tesamorelin?

Accepted Answer

Clinical trial data shows that visceral fat reaccumulates to near-baseline levels within 3-6 months of discontinuing tesamorelin. IGF-1 levels return to pre-treatment baseline. This means tesamorelin's benefits require ongoing treatment — it does not produce permanent structural changes in fat distribution.

Question 8

GHRH Receptor Activation Tesamorelin binds to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. The mechanism is fundamentally the same as natural GHRH — the hexenoic acid modification improves pharmacokinetics without altering receptor binding or downstream signaling. Like sermorelin, tesamorelin preserves the hypothalamic-pituitary feedback axis. Growth hormone and IGF-1 released in response to tesamorelin feed back to suppress further GH release through somatostatin and direct pituitary effects. This provides inherent dose-limiting protection against GH excess — a safety advantage over direct GH injection. Why Visceral Fat Specifically?

Accepted Answer

The question most people ask about tesamorelin is why it's specifically effective for visceral fat rather than subcutaneous fat or total body weight. The answer involves GH's preferential effects on visceral adipose tissue (VAT). Visceral adipocytes have a higher density of GH receptors and greater sensitivity to GH-mediated lipolysis compared to subcutaneous adipocytes. When GH levels increase, visceral fat is preferentially mobilized because these cells are more responsive to GH's lipolytic signals. This is not unique to tesamorelin — it's a property of GH biology generally — but tesamorelin's robust GH stimulation makes this effect clinically meaningful and measurable. Additionally, visceral fat accumulation itself is associated with relative GH deficiency. Visceral adiposity suppresses

#	Vendor	Avg score	Purity range	Tests	Verified $/mg	Grade	Profile
Grade B+ — Very Good
1	Peptide Partners	7.8	97.8 – 99.0%	11	$2.80	B+	review →

Vendor Rankings

Tesamorelin Rankings